The impact of ABO and RhD blood types on Babesia microti infection

Authors:

Abstract
Background: Babesiosis is an emerging infectious disease caused by intraerythrocyticBabesiaparasites that can cause severe disease and death. While blood type is known to affect the mortality ofPlasmodium falciparummalaria patients, associations between red blood cell (RBC) antigens andBabesia microtiinfection and disease severity are lacking.Methods: We evaluated RhD and ABO blood types ofBabesia-infected (18S rRNA reactive) blood donors in 10 endemic states in the Northeastern and northern Midwestern United States. We also assessed possible associations between RhD and ABO blood types and disease severity among hospitalized babesiosis patients in Connecticut.Results: A total of 768Babesia-infected blood donors were analyzed, of which 750 (97.7%) had detectableB.microti-specific antibodies.B.microti-infected blood donors were more likely to be RhD- (OR of 1.22, p-value 0.024) than RhD+ donors. Hospitalized RhD- babesiosis patients were more likely than RhD+ patients to have high peak parasitemia (p-value 0.017), which is a marker for disease severity. No differences in RhD+ blood type were noted between residents of the Northeast (OR of 0.82, p-value 0.033) and the Midwest (OR of 0.74, p-value 0.23). Overall, ABO blood type was not associated with blood donorB.microtiinfection, however,B.microti-infected donors in Maine and New Jersey were more likely to be blood type B compared to non-type B (OR 2.49 [p = 0.008] and 2.07 [p = 0.009], respectively), while infected donors from Pennsylvania were less likely to be type B compared to non-type B (OR 0.32 [p = 0.02]).Conclusions: People expressing RhD antigen may have a decreased risk ofB.microtiinfection and babesiosis severity. The association of B antigen withB.microtiinfection is less clear because the antigen appeared to be less prevalent in infected Pennsylvania blood donors but more prevalent in Maine and New Jersey infected donors. Future studies should quantify associations betweenB.microtigenotypes, RBC antigens, and the frequency and severity ofB.microtiinfection to increase our understanding of humanBabesiapathogenesis and improve antibody, vaccine, and RBC exchange transfusion strategies.
Funding Information
  • Llura A. Gund Laboratory for Vector-borne Diseases
  • Gordon and Llura Gund Foundation
  • NIH (K12HL141953)

This publication has 40 references indexed in Scilit: